Changes to the Funding of Directly Acting Antiviral (DAA) Treatments in Hepatitis C 15 Jun 2016

Pharmac has announced some important changes to the funding of directly acting antiviral (DAA) treatments in Hepatitis C.

Pharmac has announced some important changes to the funding of directly acting antiviral (DAA) treatments in Hepatitis C.

These effect possible treatment options for those with the virus, depending on severity and genotype. Kate Grimwade has written a summary of these which can be accessed here and more information will be disseminated soon.